Showing 2001-2010 of 3223 results for "".
- Bausch + Lomb Launches Alaway Preservative Free Antihistamine Eye Dropshttps://modernod.com/news/bausch-lomb-launches-alaway-preservative-free-antihistamine-eye-drops/2478902/Bausch + Lomb announced the US launch of Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. Bausch + Lomb says Alaway is the first and only over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the FDA.
- Allergan Launches Refresh Digital Lubricant Eye Dropshttps://modernod.com/news/abbvie-launches-refresh-digital-lubricant-eye-drops/2478901/Allergan announced the over-the-counter (OTC) launch of Refresh Digital, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. Refresh Digital features proprietary HydroCell technology that supports all three layers of the te
- Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the UShttps://modernod.com/news/alcon-announces-broad-retail-availability-of-pataday-once-daily-relief-extra-strength-in-the-u-s/2478886/Alcon announced that Pataday Once Daily Relief Extra Strength is now available in-store and online at U.S. retailers following its 2020 approval by the FDA for sale over the counter (OTC). As Alcon’s third Rx-to-OTC switch in the past 12 months, Pataday Once Daily Relief Extra Strength (o
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we
- Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Designhttps://modernod.com/news/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design/2478835/Aldeyra Therapeutics announced the finalization of the design of the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry
- NeuroVision Imaging Receives Funding From the ADDF to Develop Biomarkers to Diagnose Alzheimer’s and Related Dementiashttps://modernod.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/NeuroVision Imaging announced it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders. “Many of the existing diagnostic
- Alcon Canada Introduces the Clareon IOL with the AutonoMe Preloaded Intraocular Lens Delivery Systemhttps://modernod.com/news/alcon-canada-introduces-the-clareon-iol-with-the-autonome-preloaded-intraocular-lens-delivery-system/2478820/Alcon has announced a nationwide launch of the Clareon IOL with the AutonoMe delivery system in Canada. AutonoMe is an automated, disposable, preloaded IOL delivery system that enables precise delivery of the IOL into the capsular bag in patients undergoing cataract surgery, according to
- Lensar Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrellhttps://modernod.com/news/lensar-expands-board-of-directors-with-the-appointments-of-aimee-s-weisner-and-elizabeth-g-ofarrell/2478817/Lensar announced the expansion of its board of directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. In addition to serving on the company’s Board of Directors, Ms. Weisner will
- Elizabeth Yeu, MD, and K. Peony Yu, MD, Appointed to Staar Surgical Board of Directorshttps://modernod.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/Staar Surgical announced the appointments of Elizabeth Yeu, MD, Partner, Virginia Eye Consultants, and K. Peony Yu, MD, retired Chief Medical Officer, FibroGen, to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Dir
- Preliminary Results From Aldeyra’s Phase 3 Tranquility Trial Offer Promise for Patients With Dry Eye Syndrome, Says GlobalDatahttps://modernod.com/news/preliminary-results-from-aldeyras-phase-3-tranquility-trial-offer-promise-for-patients-with-dry-eye-syndrome-says-globaldata/2478786/Aldeyra Therapeutics recently announced topline results from the run-in cohort of the phase 3 trial evaluating reproxalap 0.25% for patients with dry eye syndrome (DES). The positive impact of the therapy on endpoints, such as ocular dryness, discomfort and Schirmer’s test, although preliminary,